Sumitomo Mitsui Trust Holdings Inc. Has $19.19 Million Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Sumitomo Mitsui Trust Holdings Inc. trimmed its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZFree Report) by 1.9% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 159,317 shares of the specialty pharmaceutical company’s stock after selling 3,117 shares during the quarter. Sumitomo Mitsui Trust Holdings Inc. owned 0.25% of Jazz Pharmaceuticals worth $19,185,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in JAZZ. Vestal Point Capital LP acquired a new position in Jazz Pharmaceuticals in the 4th quarter valued at $89,175,000. Armistice Capital LLC grew its holdings in Jazz Pharmaceuticals by 108.4% in the 4th quarter. Armistice Capital LLC now owns 651,626 shares of the specialty pharmaceutical company’s stock valued at $80,150,000 after buying an additional 338,882 shares in the last quarter. Pacer Advisors Inc. grew its holdings in Jazz Pharmaceuticals by 28.1% in the 4th quarter. Pacer Advisors Inc. now owns 1,023,706 shares of the specialty pharmaceutical company’s stock valued at $125,916,000 after buying an additional 224,865 shares in the last quarter. Perpetual Ltd grew its holdings in Jazz Pharmaceuticals by 54.0% in the 1st quarter. Perpetual Ltd now owns 475,018 shares of the specialty pharmaceutical company’s stock valued at $57,202,000 after buying an additional 166,543 shares in the last quarter. Finally, Baupost Group LLC MA grew its holdings in Jazz Pharmaceuticals by 23.7% in the 4th quarter. Baupost Group LLC MA now owns 833,696 shares of the specialty pharmaceutical company’s stock valued at $102,545,000 after buying an additional 160,000 shares in the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently weighed in on JAZZ shares. Needham & Company LLC cut their target price on Jazz Pharmaceuticals from $222.00 to $210.00 and set a “buy” rating for the company in a research report on Thursday, June 20th. Piper Sandler upped their target price on Jazz Pharmaceuticals from $171.00 to $188.00 and gave the company an “overweight” rating in a research report on Wednesday, March 20th. Cantor Fitzgerald reiterated an “overweight” rating and set a $180.00 target price on shares of Jazz Pharmaceuticals in a research report on Wednesday, April 10th. Truist Financial reiterated a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 20th. Finally, Stifel Nicolaus upped their target price on Jazz Pharmaceuticals from $225.00 to $230.00 and gave the company a “buy” rating in a research report on Friday, March 15th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $188.62.

Check Out Our Latest Analysis on Jazz Pharmaceuticals

Jazz Pharmaceuticals Price Performance

Jazz Pharmaceuticals stock opened at $100.57 on Wednesday. The company has a current ratio of 2.27, a quick ratio of 1.90 and a debt-to-equity ratio of 1.38. The company has a market capitalization of $6.34 billion, a PE ratio of 20.74, a P/E/G ratio of 1.55 and a beta of 0.58. Jazz Pharmaceuticals plc has a 12 month low of $99.74 and a 12 month high of $146.70. The stock has a 50-day moving average price of $108.04 and a two-hundred day moving average price of $115.76.

Jazz Pharmaceuticals (NASDAQ:JAZZGet Free Report) last posted its earnings results on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 EPS for the quarter, missing the consensus estimate of $3.53 by ($1.55). The firm had revenue of $901.98 million during the quarter, compared to the consensus estimate of $938.99 million. Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. Analysts expect that Jazz Pharmaceuticals plc will post 15.35 EPS for the current year.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, EVP Neena M. Patil sold 5,000 shares of the stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $109.65, for a total value of $548,250.00. Following the completion of the sale, the executive vice president now owns 36,629 shares of the company’s stock, valued at $4,016,369.85. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 4.20% of the company’s stock.

About Jazz Pharmaceuticals

(Free Report)

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Further Reading

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals plc (NASDAQ:JAZZFree Report).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.